Market's view on Shield Thera
Published on April 2024
- Concerns about insider trading and how it reflects on the integrity of board members.
- Speculation on whether upcoming financial results will reveal an increase in prescriptions and a boost to profits or reduced losses, given the current low share price.
- Allegations of leaked internal results, which is considered unethical and similar to playing poker with a marked deck.
- A significant sale of over 1 million shares is under scrutiny, questioning whether it marks the end of a seller’s influence.
- Discussion on a director’s purchase of 2 million shares at a low price and potential market value increase within five months.
- Multiple stock watchers express differing views on the company’s management, with some emphasising its critical role and others focusing on past bullishness despite poor company performance.
- The intellectual property is valued at over £100 million, which seems disproportionate to the current low share price.
- Debate over the company’s past, its risk profile, and whether it still makes sense to raise funds or opt for short-term borrowing.
- Concerns about potential share dilution and manipulation of share prices, especially in small to medium enterprises.
- Allegations of insider trading prior to official announcements, with historical patterns of share selling before announcements that turn out to be judicious.
- Expectations are set for the upcoming results announcement, with some watchers optimistically predicting a significant rise in share price if the results are positive.
- Historical insider selling ahead of fundraisings noted as a red flag, particularly when the share price was significantly higher.